Stock listing

NASDAQ:BCAB BioAtla, Inc. Stock

Home listing (NASDAQ) of BioAtla, Inc.

Follow BioAtla, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:BCAB

$1.55 USD +0.26 (+20.2%)

Close on Nov 20, 2026

Past year -97.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.22 – $1.55 USDNov 20, 2026
Volume
3,802 sharesNov 20, 2026
Market cap
$2.58M USDAt the close on Nov 20, 2026 · price × 1.67M shares outstanding
52-week range
$1.07 – $59.50 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$80,802 USDMedian day 9,597 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
BioAtla, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:BCAB · Home$1.55 USD+0.26 (+20.2%)3,802$1.55$1.55$1.22$1.29Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BCAB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.55+0.26+20.2%$1.55$1.55$1.223,802
$1.29-0.064-4.7%$1.30$1.50$1.2914,095
$1.354-0.446-24.8%$1.52$1.528$1.2812,756
$1.80-0.19-9.5%$2.00$2.098$1.7913,018
$1.99+0.43+27.6%$1.79$2.01$1.7629,562
$1.56-0.13-7.7%$1.56$1.56$1.56564
$1.69-0.16-8.6%$1.55$1.70$1.521,518
$1.85+0.02+1.1%$1.75$1.85$1.515,580
$1.83-0.26-12.4%$2.00$2.00$1.5413,147
$2.09+0.09+4.5%$1.87$2.18$1.4721,421
$2.00-0.09-4.3%$1.65$2.061$1.606,400
$2.09+0.09+4.5%$2.14$2.14$1.5847,043
$2.000.000.0%$1.903$2.00$1.865,224
$2.00-0.06-2.9%$2.08$2.08$2.00674
$2.06-0.04-1.9%$2.11$2.11$2.061,009
$2.100.000.0%$2.20$2.20$1.902,645
$2.10+0.10+5.0%$1.59$2.10$1.591,002
$2.00-0.062-3.0%$2.02$2.02$1.714,611
$2.062+0.102+5.2%$1.95$2.074$1.63828,320
$1.96+0.25+14.6%$1.75$1.96$1.754,358
$1.71+0.48+39.0%$1.40$1.76$1.407,323
$1.23-0.126-9.3%$1.445$1.55$1.235,232
$1.356+0.026+2.0%$1.34$1.50$1.343,617
$1.33+0.02+1.5%$1.36$1.525$1.305,337
$1.31-0.05-3.7%$1.22$1.31$1.222,183
$1.36+0.06+4.6%$1.36$1.36$1.221,412
$1.300.000.0%$1.30$1.30$1.293,283
$1.30+0.02+1.6%$1.29$1.30$1.253,911
$1.28+0.03+2.4%$1.28$1.28$1.2711,852
$1.25-0.25-16.7%$1.39$1.39$1.2499,317
$1.50-0.05-3.2%$1.55$1.57$1.342,906
$1.55-0.04-2.5%$1.65$1.65$1.505,829
$1.59+0.24+17.8%$1.23$1.59$1.2310,118
$1.35+0.03+2.3%$1.31$1.46$1.2211,086
$1.32+0.01+0.8%$1.31$1.32$1.231,390
$1.31+0.05+4.0%$1.23$1.65$1.233,477
$1.26-0.04-3.1%$1.45$1.45$1.263,495
$1.30-0.06-4.4%$1.45$1.45$1.26316,735
$1.36-0.16-10.5%$1.55$1.65$1.366,530
$1.52+0.04+2.7%$1.48$1.88$1.38411,050
$1.48-0.04-2.6%$1.31$1.48$1.1710,813
$1.52-0.07-4.4%$1.41$1.58$1.411,979
$1.59-0.18-10.2%$1.75$1.78$1.3135,105
$1.77-0.15-7.8%$1.74$1.77$1.4412,652
$1.92+0.13+7.3%$1.71$2.03$1.4121,983
$1.79-0.11-5.8%$1.75$1.79$1.652,868
$1.90-0.50-20.8%$2.50$2.50$1.4073,927
$2.40+1.03+75.2%$1.429$2.50$1.416107,398
$1.37-0.10-6.8%$1.50$1.52$1.349,632
$1.47-0.03-2.0%$1.54$1.54$1.3118,692
$1.50+0.32+27.1%$1.27$1.55$1.1027,727
$1.18-0.05-4.1%$1.25$1.28$1.18881
$1.23-0.03-2.4%$1.30$1.45$1.1814,900
$1.26-0.06-4.5%$1.35$1.45$1.1640,000
$1.32+0.02+1.5%$1.25$1.39$1.1619,100
$1.30+0.095+7.9%$1.17$1.30$1.1514,800
$1.205+0.125+11.6%$1.08$1.40$1.0820,300
$1.08-0.61-36.1%$1.51$1.70$1.07117,500
$1.69-0.045-2.6%$1.76$2.13$1.31130,200
$1.735-1.405-44.7%$1.58$2.10$1.511,034,080
$3.14+0.02+0.6%$3.15$3.245$3.0731,334
$3.12-0.14-4.3%$3.35$3.37$3.0621,465
$3.26-0.02-0.6%$3.28$3.47$3.0955,312
$3.28+0.10+3.1%$3.27$4.00$3.10393,763
$3.180.000.0%$3.26$3.41$3.0388,744
$3.18-0.09-2.8%$3.24$3.35$3.1419,035

Splits

1 split · NASDAQ:BCAB · every price before a split is adjusted for it

DayRatioWhat
1-for-50Consolidation
Ticker
NASDAQ:BCAB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

BioAtla Announces Share Consolidation

Mar 31, 2026

Closed $8.05 (+4.5%) on Mar 31, 2026

All BioAtla, Inc. news

BioAtla, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
4 in the last 12 months · 96 in all · newest Mar 31, 2026 · oldest 2020
Calls
15 calls with a replay · 15 with a transcript · latest Nov 13, 2025
Decks
11 decks · latest Mar 31, 2026

Where BioAtla, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:BCAB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:BCABBOATSUnited StatesUSD

Valuation

Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$2.01M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
Negative equity
Beta vs S&P 500
-0.34

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
BioAtla, Inc. · NASDAQ:BCABUS$2.58MUS$2.01Mn/an/an/an/an/an/a-0.34
Alligator Bioscience AB · OMXSTO:ATORXUS$2.79MUS$1.47Mn/a53.3×n/a1.2×n/a1.2×n/a
Traws Pharma, Inc. · NASDAQ:TRAWUS$2.69MUS$351,448n/an/an/an/an/an/a2.07
NextCell Pharma AB · OMXSTO:NXTCLUS$2.69MUS$626,140n/a0.6×n/a0.6×−440.8%0.0×n/a
Bioxytran, Inc. · OTC:BIXTUS$2.66MUS$2.59Mn/an/an/an/an/an/a-1.20
Invion Ltd. · ASX:IVXUS$2.49MUS$3.12Mn/a12.2×n/a0.7×n/a0.3×n/a
GRI Bio, Inc. · NASDAQ:GRIUS$2.45M−US$6.99Mn/an/an/a0.3×n/a0.0×0.89
NeuroSense Therapeutics Ltd. · NASDAQ:NRSNUS$2.43MUS$2.20Mn/an/an/an/an/an/a1.41
ValiRx PLC · LSE:VALUS$2.42MUS$1.15Mn/a28.0×n/a0.6×n/a0.0×n/a
BSF Enterprise PLC · LSE:BSFAUS$2.40MUS$2.95Mn/a42.7×n/a1.0×n/a0.3×n/a
Revelation Biosciences, Inc. · NASDAQ:REVBUS$2.39M−US$5.92Mn/an/an/a0.3×n/a0.1×1.66
Median of the othersUS$2.47MUS$1.31M28.0×0.6×−440.8%0.1×1.41

Forecasts

2 strong buy · 1 buy · 1 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
10.00 USD · Analysts' mean
EPS, year to Dec 2025
-1.38 · 3 analysts

Team and board

OfficerRole
Richard WaldronChief Financial Officer

Events

Calls

CallWhenStatus
BioAtla (NASDAQ:BCAB) Q3 2025 Earnings CallThu, Nov 13, 2025 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q2 2025 Earnings CallThu, Aug 07, 2025 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q1 2025 Earnings CallTue, May 06, 2025 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q4 2024 Earnings CallThu, Mar 27, 2025 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q3 2024 Earnings CallThu, Nov 07, 2024 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q2 2024 Earnings CallThu, Aug 08, 2024 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q1 2024 Earnings CallTue, May 14, 2024 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q4 2023 Earnings CallTue, Mar 26, 2024 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q3 2023 Earnings CallTue, Nov 07, 2023 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q2 2023 Earnings CallTue, Aug 01, 2023 · 4:30 PM ETReplay
All 15 calls
CallWhenStatus
BioAtla (NASDAQ:BCAB) Q1 2023 Earnings CallThu, May 11, 2023 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q4 2022 Earnings CallThu, Mar 23, 2023 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q3 2022 Earnings CallThu, Nov 03, 2022 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q2 2022 Earnings CallTue, Aug 09, 2022 · 4:30 PM ETReplay
BioAtla (NASDAQ:BCAB) Q1 2022 Earnings CallWed, May 04, 2022 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q2 2026Aug 13, 2026−8.6%
Q1 2026May 29, 2026−12.8%
Q4 2025Mar 19, 2026+5.6%
Q3 2025Nov 13, 2025 · After close+19.7%
Q2 2025Aug 7, 2025 · After close−7.1%
Q1 2025May 6, 2025 · After close−5.7%
Q4 2024Mar 24, 2025 · Before open+5.4%
Q3 2024Nov 7, 2024 · After close−5.4%
Q2 2024Aug 8, 2024 · After close0.0%
Q1 2024May 14, 2024 · After close+14.9%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 26, 2024 · After close+14.9%
Q3 2023Nov 7, 2023 · After close−6.3%
Q2 2023Aug 1, 2023 · After close+3.5%
Q1 2023May 11, 2023 · After close+14.3%
Q4 2022Mar 23, 2023 · After close+2.6%
Q3 2022Nov 4, 2022 · Before open+18.7%
Q2 2022Aug 9, 2022 · After close+83.1%
Q1 2022May 5, 2022 · After close−9.2%
Q4 2021Mar 1, 2022 · Before open−0.5%
Quarter to Sep 30, 2021Nov 15, 2021 · After close+2.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2026)Investor deck82 slidesMar 31, 2026
Q3 2025 Earnings PresentationEarnings70 slidesNov 13, 2025
Q1 2025 Earnings PresentationEarnings66 slidesMay 6, 2025
Investor Presentation (December 2024)Investor deck49 slidesDec 20, 2024
Technical Presentation (October 2024)Technical14 slidesOct 11, 2024
ESMO Sarcoma and Rare Cancers 2024Conference16 slidesMarch 2024
Investor Presentation (January 2024)Investor deck55 slidesJan 9, 2024
Technical Presentation (December 2023)Technical8 slidesDec 4, 2023
AACR 2020 Virtual Annual Meeting IIConference14 slidesFebruary 2023
Corporate Update (November 2022)Corporate update11 slidesNov 4, 2022
All 11 decks
DeckKindSlidesDate
Needham & Co Annual Healthcare Conference 2022Conference19 slidesApr 11, 2022

Open Decks

Financings

RaiseDate
Pre-paid advance convertible into common stock
Closed: US$7.13M raised · Tungsten Advisors
Dealers: Tungsten Advisors (lead)
Buyers: Yorkville Advisors Global (affiliate) (part of an aggregate $7.5 million advance); Anson Advisors Inc. (funds managed by) (part of an aggregate $7.5 million advance)
Use of proceeds: Support operations while finalizing a strategic partnership
Nov 21, 2025
Common stock under Standby Equity Purchase Agreement
Announced: Tungsten Advisors
Dealers: Tungsten Advisors (lead)
Buyers: Yorkville Advisors Global (affiliate) (commitment to buy up to a total of $15 million of common stock if the Company exercises its option)
Use of proceeds: Support operations while finalizing a strategic partnership
Nov 21, 2025
Registered direct offering of shares of common stock with accompanying warrants
Announced: about US$9.2M · US$0.952 a share · Warrants at US$1.19 for 66 months · Tungsten Advisors (through its Broker-Dealer, Finalis Securities LLC)
Dealers: Tungsten Advisors (through its Broker-Dealer, Finalis Securities LLC) (lead)
Use of proceeds: Research and development including BA3182 and mecbotamab vedotin data readouts, partnering activities, working capital and general corporate purposes
Dec 20, 2024

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Dec 15, 2020.

Price
US$18.00 a share
Shares offered
10,500,000 shares of common stock
Offering size
US$189 million
Underwriters' option
Up to 1,575,000 more shares
Underwriters
J.P. Morgan, Jefferies, Credit Suisse, BTIG · In the order on the cover
Shares delivered
On or about Dec 18, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceOct 6, 2020
Filed publiclyNov 13, 2020
Amended twiceNewest Dec 9, 2020
Shares registered with an exchangeDec 9, 2020
Declared effective by the SECDec 15, 2020
Final prospectus, with the priceDec 17, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Dec 17, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue300.0K
Research and development43.6M63.1M103.7M79.3M58.3M19.9M25.9M
Operating income-59.3M-73.9M-129.7M-108.1M-96.4M-30.1M-28.3M
Depreciation and amortization373.0K925.0K1.22M1.20M1.33M1.01M860.0K
EBITDA-58.9M-73.0M-128.5M-106.9M-95.1M-29.1M-27.4M
Interest expense03.00K1.39M1.63M
Income tax000000
Net income-59.6M-69.8M-123.5M-106.5M-95.4M-35.9M-29.9M
Earnings per share, basic-1.01-1.44-2.58-2.74-2.76-3.19
Earnings per share, diluted-1.01-1.44-2.58-2.74-2.76-3.19

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents7.12M49.0M111.5M215.5M245.0M238.6M3.70M
Receivables0
Current assets8.01M51.2M116.4M220.4M247.3M240.7M
Property, plant and equipment120.0K678.0K1.60M2.73M3.68M4.10M
Total assets13.8M52.4M119.7M225.7M254.4M244.9M
Accounts payable8.19M1.90M3.82M4.23M1.18M2.46M
Current liabilities21.9M14.5M28.3M23.1M19.8M32.3M
Total liabilities50.0M38.2M49.0M45.4M43.6M35.0M
Shareholders' equity-36.2M14.3M70.7M180.3M210.8M210.0M-56.0M
Shares outstanding1.27M58.1M48.1M46.3M35.8M32.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-48.2M-71.9M-104.0M-90.4M-62.2M-36.3M-9.64M
Cash from investing0-98.0K-265.0K-924.0K-590.0K-1.51M
Cash from financing6.28M9.51M77.0K61.2M69.5M271.8M4.00M
Change in cash-41.9M-62.4M-104.0M-29.5M6.37M234.9M-7.16M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveOct 30, 2026Other filingsSEC
424B3 · ProspectusOct 29, 2026Offer documentSEC
RW · Request to withdraw a registrationOct 27, 2026Other filingsSEC
S-1 · Registration statementOct 19, 2026Offer documentSEC
8-K · Current reportOct 19, 2026Material contractSEC
8-K · Current reportSep 29, 2026Management or board changeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
4 · Change in ownershipSep 2, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 28, 2026Current reportSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportJul 16, 2026Meeting outcomeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
4 · Change in ownershipJun 5, 2026Insider tradeSEC
ARS · Annual report to shareholdersJun 3, 2026Annual reportSEC
DEFA14A · Additional proxy materialJun 3, 2026Meeting noticeSEC
DEF 14A · Proxy statementJun 3, 2026Meeting noticeSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
10-K/A · Annual report, amendedApr 29, 2026Annual reportSEC
8-K · Current reportApr 2, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 31, 2026Offer documentSEC
10-K · Annual reportMar 31, 2026Annual reportSEC
8-K · Current reportMar 31, 2026ResultsSEC
8-K · Current reportMar 23, 2026Management or board changeSEC
424B2 · ProspectusMar 20, 2026Offer documentSEC
424B2 · ProspectusMar 13, 2026Offer documentSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
424B2 · ProspectusMar 6, 2026Offer documentSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
4 · Change in ownershipMar 2, 2026Insider tradeSEC
DEFA14A · Additional proxy materialMar 2, 2026Meeting noticeSEC
8-K · Current reportMar 2, 2026ResultsSEC
DEFM14AFeb 11, 2026Meeting noticeSEC
8-K · Current reportFeb 9, 2026Current reportSEC
8-K · Current reportFeb 6, 2026Current reportSEC
PREM14AJan 30, 2026Other filingsSEC
8-K · Current reportJan 30, 2026Meeting outcomeSEC
S-3 · Registration statementJan 16, 2026Offer documentSEC
DEFA14A · Additional proxy materialJan 15, 2026Meeting noticeSEC
8-K · Current reportJan 12, 2026Meeting outcomeSEC
DEFA14A · Additional proxy materialDec 31, 2025Meeting noticeSEC
8-K · Current reportDec 31, 2025Material contractSEC
8-K · Current reportDec 30, 2025Meeting outcomeSEC
DEF 14A · Proxy statementDec 5, 2025Meeting noticeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementNov 24, 2025Meeting noticeSEC
424B5 · ProspectusNov 21, 2025Offer documentSEC
8-K · Current reportNov 21, 2025Material contractSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 15, 2025Big-stake noticeSEC
8-K · Current reportSep 22, 2025Current reportSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
4 · Change in ownershipSep 2, 2025Insider tradeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
8-K · Current reportJun 20, 2025Management or board changeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 20, 2025Big-stake noticeSEC
8-K · Current reportMay 16, 2025Current reportSEC
424B3 · ProspectusMay 16, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 15, 2025Other filingsSEC
CORRESP · Letter to the SECMay 12, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 9, 2025Other filingsSEC
S-3 · Registration statementMay 6, 2025Offer documentSEC
10-Q · Quarterly reportMay 6, 2025Quarterly reportSEC
8-K · Current reportMay 6, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 25, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 24, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 28, 2025Offer documentSEC
10-K · Annual reportMar 27, 2025Annual reportSEC
8-K · Current reportMar 27, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeMar 18, 2025Big-stake noticeSEC
8-K · Current reportMar 14, 2025Management or board changeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
4 · Change in ownershipFeb 24, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 10, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 7, 2025Big-stake noticeSEC
8-K · Current reportFeb 7, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 24, 2025Big-stake noticeSEC
424B5 · ProspectusDec 20, 2024Offer documentSEC
8-K · Current reportDec 20, 2024Material contractSEC
8-K · Current reportDec 20, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SC 13D/A · Big-stake notice, amendedOct 2, 2024Big-stake noticeSEC
8-K · Current reportSep 23, 2024Material contractSEC
SC 13D/A · Big-stake notice, amendedSep 6, 2024Big-stake noticeSEC
4 · Change in ownershipSep 3, 2024Insider tradeSEC
4 · Change in ownershipSep 3, 2024Insider tradeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
SC 13G · Big-stake noticeAug 7, 2024Big-stake noticeSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
4 · Change in ownershipAug 1, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJul 8, 2024Big-stake noticeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
8-K · Current reportJun 13, 2024Meeting outcomeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
8-K · Current reportMay 17, 2024Current reportSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
4 · Change in ownershipMay 1, 2024Insider tradeSEC
8-K · Current reportApr 24, 2024Current reportSEC
ARS · Annual report to shareholdersApr 24, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2024Meeting noticeSEC
SC 13D/A · Big-stake notice, amendedApr 16, 2024Big-stake noticeSEC
4 · Change in ownershipApr 1, 2024Insider tradeSEC
4 · Change in ownershipApr 1, 2024Insider tradeSEC
S-8 · Registration statement for employee plansMar 26, 2024Offer documentSEC
10-K · Annual reportMar 26, 2024Annual reportSEC
8-K · Current reportMar 26, 2024ResultsSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
8-K · Current reportFeb 21, 2024Management or board changeSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
4 · Change in ownershipFeb 20, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
8-K · Current reportFeb 12, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
SC 13G · Big-stake noticeJan 29, 2024Big-stake noticeSEC
4 · Change in ownershipJan 19, 2024Insider tradeSEC
8-K · Current reportJan 9, 2024Current reportSEC
8-K · Current reportJan 8, 2024Current reportSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipDec 26, 2023Insider tradeSEC
4 · Change in ownershipDec 20, 2023Insider tradeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
8-K · Current reportDec 13, 2023Current reportSEC
8-K · Current reportDec 4, 2023Current reportSEC
4 · Change in ownershipDec 1, 2023Insider tradeSEC
4 · Change in ownershipDec 1, 2023Insider tradeSEC
10-Q · Quarterly reportNov 7, 2023Quarterly reportSEC
8-K · Current reportNov 7, 2023ResultsSEC
4 · Change in ownershipNov 2, 2023Insider tradeSEC
4 · Change in ownershipNov 2, 2023Insider tradeSEC
4 · Change in ownershipNov 1, 2023Insider tradeSEC
4 · Change in ownershipNov 1, 2023Insider tradeSEC
4 · Change in ownershipNov 1, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 3, 2023Insider tradeSEC
4 · Change in ownershipOct 2, 2023Insider tradeSEC
4 · Change in ownershipOct 2, 2023Insider tradeSEC
4 · Change in ownershipOct 2, 2023Insider tradeSEC
4 · Change in ownershipOct 2, 2023Insider tradeSEC
4 · Change in ownershipOct 2, 2023Insider tradeSEC
4 · Change in ownershipSep 13, 2023Insider tradeSEC
4 · Change in ownershipSep 1, 2023Insider tradeSEC
4 · Change in ownershipSep 1, 2023Insider tradeSEC
4 · Change in ownershipSep 1, 2023Insider tradeSEC
4 · Change in ownershipSep 1, 2023Insider tradeSEC
4 · Change in ownershipSep 1, 2023Insider tradeSEC

This page holds 200 of 510 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from BioAtla, Inc.’s releases · as of Nov 21, 2025

Common shares
1,666,100
Fully diluted
1,666,100

Fully diluted

LineShares
Common shares1,666,100

Share count over time

CountShares
Nov 22, 20261,666,100

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Barclays2<0.01%US$3Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund9,1640.55%US$37,939Jun 30, 2026
Fidelity Extended Market Index Fund6,1280.37%US$24,083May 31, 2026
Fidelity Total Market Index Fund1,6100.10%US$6,327May 31, 2026
Fidelity Series Total Market Index Fund1,4560.09%US$5,722May 31, 2026
Fidelity Nasdaq Composite Index Fund165<0.01%US$648May 31, 2026
State Street Balanced Index Fund25<0.01%US$104Jun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Mary Ann Gray
Other companies: Keros Therapeutics, Inc. (Director · Since at least Jun 1, 2022); Compass Therapeutics, Inc. (Director · Since at least Apr 26, 2022); RAPT Therapeutics Inc (Director · Since at least Mar 31, 2022); Palisade Bio, Inc. (Director · Jun 11, 2023 – Nov 21, 2023 · Past)
Director · Since at least Jun 16, 2022
Susan Moran
Other companies: Crescent Biopharma, Inc. (Director · Since at least Jun 13, 2025); Tyra Biosciences, Inc. (Board member · Since at least May 7, 2024); RayzeBio, Inc. (CHIEF MEDICAL OFFICER · Sep 14, 2023 – Feb 26, 2024 · Past)
Director · Since at least Dec 15, 2020
Eddie Williams
Other companies: BiomX Inc. (Director · Oct 12, 2023 – Apr 14, 2025 · Past); Gyre Therapeutics, Inc. (Director · Jan 2, 2018 – Jan 7, 2022 · Past)
Director · Since at least Dec 16, 2021
Lawrence Steinman
Other companies: Pasithea Therapeutics Corp. (Director · Since at least Sep 14, 2021); Forum Markets, Incorporated (Director · Since at least Nov 6, 2020)
Director · Since at least Dec 15, 2020
Scott A. Smith
Other companies: Viatris Inc. (Chief Executive Officer, Director · Since at least Dec 29, 2022); Apexigen Inc. (Director · Jul 29, 2022 – Aug 23, 2023 · Past)
Director · Since at least Mar 31, 2022
Jay M Phd Short
Other companies: Senomyx Inc (Director · May 24, 2006 – May 20, 2016 · Past)
Chief Executive Officer, Director · Since at least Dec 15, 2020
Priyanka Belawat
Other companies: Iteos Therapeutics Inc (Director · Jul 23, 2020 – Jul 23, 2020 · Past)
Director · Dec 15, 2020 – Dec 15, 2020 · Past
Carolyn Anderson ShortSee Remarks · Dec 15, 2020 – Dec 15, 2020 · Past
Christian VasquezChief Financial Officer · Since at least Dec 15, 2020
Eric SieversChief Medical Officer · Since at least Dec 15, 2020
All 12 people
PersonSeat
Richard WaldronChief Financial Officer · Since at least Dec 15, 2020
Sylvia McBrinnDirector · Since at least Jun 15, 2021

Open People

Log in to ask 6ix AI your own questions about BioAtla, Inc.